AI filing briefs · archive

8-K filings in November 2026, explained

2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

6 of 2,354 briefs match

newest first · times in ET

Pantages Capital Acquisition gets until March 1, 2027 to meet Nasdaq holder rule

Negative legal/regulatory Written later 8.01

Pantages Capital Acquisition Corporation received a Nasdaq extension to regain compliance with the minimum 400 Total Holders requirement for its Class A ordinary shares. The company must file proof of at least 400 Total Holders by March 1, 2027, or Nasdaq will provide notice that its securities will be delisted, with a right to appeal to a Listing Qualifications Panel.

  • Nasdaq notice of non-compliance with Listing Rule 5450(a)(2) was received September 2, 2026
  • Company submitted its compliance plan to Nasdaq on October 16, 2026
  • Nasdaq granted an extension on October 27, 2026; deadline to file holder documentation is March 1, 2027
  • If requirement is not met, Nasdaq will issue a delisting notice; the company may appeal to a Listing Qualifications Panel
Read the filing on SEC.gov ↗
WTRGEssential Utilities, Inc. Nov 5, 4:40 PM ET

Essential Utilities: Stipulation of settlement filed in New Jersey merger proceeding with American Water

Neutral legal/regulatory 8.01

Essential Utilities disclosed that American Water, Essential Utilities and their affiliates filed a Stipulation of Settlement with the New Jersey Board of Public Utilities (NJBPU) on November 2, 2026, in the proceeding to approve the proposed merger. The stipulation was entered into with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel, and is subject to review and approval by the NJBPU. The filing shows progress on regulatory approval, but the merger still requires the NJBPU's approval before it can proceed.

  • Stipulation of Settlement filed November 2, 2026, with all parties in the NJBPU proceeding
  • Stipulation posted to the NJBPU website as of November 5, 2026, and remains subject to NJBPU review and approval
  • Merger agreement with American Water was signed October 26, 2025; Essential Utilities would become a wholly owned subsidiary
Read the filing on SEC.gov ↗
MYGNMYRIAD GENETICS INC Nov 5, 9:04 AM ET

Myriad Genetics detects unauthorized network access, suspends testing and order systems

Negative legal/regulatory Written later 8.01

Myriad Genetics said it detected unauthorized access to its IT network on November 2, 2026, and temporarily suspended testing operations and order management systems while it investigates. The company said most systems have returned to normal, that it is still assessing whether any patient records were accessed, and that it does not believe the incident will have a material adverse effect on its business.

  • Unauthorized access detected on November 2, 2026, within the company's IT network environment
  • Testing operations and order management systems were temporarily suspended; most systems have since returned to normal operations
  • Whether patient records were accessed is still under investigation; external experts have been engaged
  • Company states it does not believe the incident will have a material adverse effect on its business
Read the filing on SEC.gov ↗

Local Bounti gets NYSE extension to August 5, 2027 to fix market capitalization shortfall

Negative legal/regulatory Written later 8.01

Local Bounti received a notice on November 4, 2026, that the NYSE accepted its request to extend the deadline to regain compliance with the minimum market capitalization standard from November 5, 2026 to August 5, 2027. The company must reach an average global market capitalization of at least $50 million or stockholders' equity of at least $50 million by then, and the NYSE could start delisting proceedings if progress is insufficient, so shareholders face continued listing risk.

  • NYSE accepted the company's October 20, 2026 request for a nine-month extension.
  • The compliance deadline moves from November 5, 2026 to August 5, 2027, the maximum 18-month period under NYSE rules.
  • To regain compliance, the company needs average global market capitalization of at least $50 million over 30 trading days, or stockholders' equity of at least $50 million.
  • Common stock remains listed on the NYSE during the cure period, subject to quarterly NYSE reviews of progress.
Read the filing on SEC.gov ↗

Karyopharm to be delisted from Nasdaq after Chapter 11 filing; trading suspends Nov. 11

Negative legal/regulatory Written later 3.01

Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and Nasdaq notified the company on November 4 that its common stock will be delisted. The company will not appeal, and the stock is expected to move to an over-the-counter market under the symbol KPTIQ. The filing says the proposed reorganization plan gives common stock and Series A preferred holders no payment, so existing equity is expected to have no value.

  • Nasdaq trading in common stock suspends at the opening of business on November 11, 2026.
  • Common stock expected to trade over the counter under the symbol KPTIQ on or after November 11, 2026.
  • Joint prepackaged Chapter 11 plan filed November 2, 2026 provides no distribution to common or 0% Series A Convertible Perpetual Preferred Stock holders.
  • The company expects existing equity securities to have no value and holders to face a complete loss.
Read the filing on SEC.gov ↗
CGTXCOGNITION THERAPEUTICS INC Nov 5, 6:04 AM ET

Cognition Therapeutics gets Nasdaq bid-price notice; Q3 net loss narrows to $4.1 million

Mixed legal/regulatory Written later 2.023.01

Cognition Therapeutics received a Nasdaq deficiency letter on November 3, 2026, because its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027, to regain compliance, and the letter has no immediate effect on its listing. Third-quarter results showed a smaller net loss than a year earlier, but the company reported $31.5 million in cash as of September 30, 2026.

  • Nasdaq letter dated November 3, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; compliance deadline is May 3, 2027
  • Q3 2026 net loss was $4.1 million, or $(0.04) per share, versus $4.9 million, or $(0.06) per share, in Q3 2025
  • Research and development expenses rose to $5.1 million from $3.8 million, while general and administrative expenses fell to $2.3 million from $2.6 million
  • Cash and restricted cash equivalents were $31.5 million at September 30, 2026; the company estimates funding into the fourth quarter of 2027
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.